Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer
Go here to see the original:
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Recommendation and review posted by Fredricko
